VacV Biotech develops a novel oncolytic virus platform utilizing a modified vaccinia virus to create targeted cancer immunotherapies. This technology aims to enhance systemic delivery and efficacy, addressing the limitations of current cancer treatment options.
Funding
$3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current cancer treatment options often face limitations in systemic delivery and efficacy, hindering their ability to effectively target and eliminate tumors throughout the body. Metastatic cancers, such as stage 4 colorectal cancer, have a particularly poor prognosis due to the limitations of existing therapies.
Solution
VacV Biotherapeutics is developing a novel oncolytic virus platform based on a modified vaccinia virus to create targeted cancer immunotherapies. This technology enhances systemic delivery, allowing the virus to efficiently target tumor cells anywhere in the body and promote a durable anti-tumor response. The modified vaccinia virus is engineered to enhance the innate ability to activate anti-tumor immune responses. VacV's approach also demonstrates synergy with immune checkpoint inhibition, potentially broadening the therapeutic landscape for patients with difficult-to-treat cancers. The company is advancing a pipeline of pre-clinical assets toward clinical trials, with the goal of developing easy-to-administer treatments that offer significant advantages over existing options.
Target Audience
The primary target audience includes cancer patients with solid tumors, particularly those with metastatic disease, and the oncologists and medical professionals who treat them.
Features
- Modified oncolytic Vaccinia virus for enhanced systemic delivery and tumor targeting
- Engineered to stimulate potent anti-tumor immune responses
- Demonstrated synergy with immune checkpoint inhibitors
- Designed for easy administration
- Pipeline of pre-clinical assets targeting various cancers